VDR and non-small cell lung carcinoma: Nonetheless, the potential effect of osimertinib combined with VDR inhibition on the growth of EGFRm NSCLC cells may be investigated as a future direction given the fact that a VDR antagonist named MeTC7 has effective antitumor activity.[48, 49]